Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2020 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19

Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19 Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the...
November 23, 2020 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director

Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and...
October 06, 2020 07:48 ET | Source: Oxford BioMedica plc

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB)...
September 17, 2020 07:00 ET | Source: Oxford BioMedica plc

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020

OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 Oxford, UK – 17 September 2020: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell...
September 01, 2020 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
August 03, 2020 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics Oxford, UK – 3 August...
July 31, 2020 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD Oxford, UK – 31st July, 2020: Oxford Biomedica plc...
June 08, 2020 07:00 ET | Source: Oxford BioMedica plc

Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...
June 01, 2020 07:00 ET | Source: Oxford BioMedica plc

Dr Roch Doliveux appointed Non-Executive Chairman

Oxford Biomedica Appoints Dr. Roch Doliveux as Non-Executive Chairman Oxford, UK – 1 June, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell...
May 28, 2020 07:38 ET | Source: Oxford BioMedica plc

Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of...